Prediction of Liver Fibrosis in Patients with Chronic Hepatitis C by Biochemical Surrogate Markers
Muzzafar Mehdi, Ali Hyder Mugheri, Mahesh Kumar, Asif Raza Zaidi, Wali Khan, Altaf Alam
Aim: To determine the relative viability of Fibro Test with liver biopsy in location of level of necrosis and fibrosis in chronic hepatitis C patients. Study Design: Cross-sectional observational study. Place and Duration of Study: Department of Gastroenterology, Shaikh Zayed Hospital, Lahore from 1st April 2016 to 31st March 2017. Methodology: One hundred cases that had chronic hepatitis C were included. Clotting profile and liver biopsy was completed in proper hygienic conditions and samples were delivered to find Condell recording. On the same day a 10 cc specimen of blood was taken in which 3 cc for ALT, GGT and total bilirubin and 7cc for Fibro Test. Immuneturb method (ROCHE) was analyzed for fibro test while Flex® reagent cartridge was completed for ALT, GGT and total bilirubin. Results: The grades of fibrosis were found between F0 and F4. The average ages for all METAVIR status cases were 41±12 years. Pair-wise age comparison of stage F1 revealed that F2 and F3 were quite higher and significant while significant in various stages of alpha2 macroglobulin levels. Haptoglobin levels were found noteworthy with p-value 0.005 and GGT levels were found substantial with p-value <0.001. Total bilirubin levels were found noteworthy with p-value 0.003 for various groups, Apolipoprotein A1 levels were found significant with p-value <0.001 and fibro score levels for various stages with p-value <0.001. 95.6% accuracy was found for the prognosis of all stages.
Conclusion: Fibro test is a protected, reliable, advantageous and generally economical blood test that uses six blood serum markers to make a score that relates well with the level of hepatic fibrosis. Fibro Test has been broadly approved in patients with hepatitis C.
Keywords: Fibro Test, fibrosis grade, necrosis, chronic hepatitis C